Literature DB >> 34006899

Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells.

Nirupama D Verma1,2, Andrew D Lam3,4, Christopher Chiu3,4, Giang T Tran3,4, Bruce M Hall3,4, Suzanne J Hodgkinson5,6,7.   

Abstract

Resting and activated subpopulations of CD4+CD25+CD127loT regulatory cells (Treg) and CD4+CD25+CD127+ effector T cells in MS patients and in healthy individuals were compared. Peripheral blood mononuclear cells isolated using Ficoll Hypaque were stained with monoclonal antibodies and analysed by flow cytometer. CD45RA and Foxp3 expression within CD4+ cells and in CD4+CD25+CD127loT cells identified Population I; CD45RA+Foxp3+, Population II; CD45RA-Foxp3hi and Population III; CD45RA-Foxp3+ cells. Effector CD4+CD127+ T cells were subdivided into Population IV; memory /effector CD45RA- CD25-Foxp3- and Population V; effector naïve CD45RA+CD25-Foxp3-CCR7+ and terminally differentiated RA+ (TEMRA) effector memory cells. Chemokine receptor staining identified CXCR3+Th1-like Treg, CCR6+Th17-like Treg and CCR7+ resting Treg. Resting Treg (Population I) were reduced in MS patients, both in untreated and treated MS compared to healthy donors. Activated/memory Treg (Population II) were significantly increased in MS patients compared to healthy donors. Activated effector CD4+ (Population IV) were increased and the naïve/ TEMRA CD4+ (Population V) were decreased in MS compared to HD. Expression of CCR7 was mainly in Population I, whereas expression of CCR6 and CXCR3 was greatest in Populations II and intermediate in Population III. In MS, CCR6+Treg were lower in Population III. This study found MS is associated with significant shifts in CD4+T cells subpopulations. MS patients had lower resting CD4+CD25+CD45RA+CCR7+ Treg than healthy donors while activated CD4+CD25hiCD45RA-Foxp3hiTreg were increased in MS patients even before treatment. Some MS patients had reduced CCR6+Th17-like Treg, which may contribute to the activity of MS.

Entities:  

Year:  2021        PMID: 34006899     DOI: 10.1038/s41598-021-88448-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  57 in total

1.  Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.

Authors:  Koen Venken; Niels Hellings; Karen Hensen; Jean-Luc Rummens; Robert Medaer; Marie B D'hooghe; Bénédicte Dubois; Jef Raus; Piet Stinissen
Journal:  J Neurosci Res       Date:  2006-06       Impact factor: 4.164

2.  Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis.

Authors:  Laure Michel; Laureline Berthelot; Ségolène Pettré; Sandrine Wiertlewski; Fabienne Lefrère; Cécile Braudeau; Sophie Brouard; Jean-Paul Soulillou; David-Axel Laplaud
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

3.  Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.

Authors:  Koen Venken; Niels Hellings; Marielle Thewissen; Veerle Somers; Karen Hensen; Jean-Luc Rummens; Robert Medaer; Raymond Hupperts; Piet Stinissen
Journal:  Immunology       Date:  2007-09-25       Impact factor: 7.397

4.  Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression.

Authors:  Koen Venken; Niels Hellings; Tom Broekmans; Karen Hensen; Jean-Luc Rummens; Piet Stinissen
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

5.  Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients.

Authors:  Giovanni Frisullo; Viviana Nociti; Raffaele Iorio; Agata K Patanella; Marcella Caggiula; Alessandro Marti; Cristina Sancricca; Francesco Angelucci; Massimiliano Mirabella; Pietro A Tonali; Anna P Batocchi
Journal:  Immunology       Date:  2008-11-07       Impact factor: 7.397

6.  Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients.

Authors:  Benedikt Fritzsching; Jürgen Haas; Fatima König; Pierre Kunz; Eva Fritzsching; Johannes Pöschl; Peter H Krammer; Wolfgang Brück; Elisabeth Suri-Payer; Brigitte Wildemann
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

7.  T regulatory cells are markers of disease activity in multiple sclerosis patients.

Authors:  Dacia Dalla Libera; Diletta Di Mitri; Alessandra Bergami; Diego Centonze; Claudio Gasperini; Maria Grazia Grasso; Simona Galgani; Vittorio Martinelli; Giancarlo Comi; Carlo Avolio; Gianvito Martino; Giovanna Borsellino; Federica Sallusto; Luca Battistini; Roberto Furlan
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

8.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.

Authors:  Nabila Seddiki; Brigitte Santner-Nanan; Jeff Martinson; John Zaunders; Sarah Sasson; Alan Landay; Michael Solomon; Warwick Selby; Stephen I Alexander; Ralph Nanan; Anthony Kelleher; Barbara Fazekas de St Groth
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

9.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

10.  Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.

Authors:  Maria Rodi; Nikolaos Dimisianos; Anne-Lise de Lastic; Panagiota Sakellaraki; George Deraos; John Matsoukas; Panagiotis Papathanasopoulos; Athanasia Mouzaki
Journal:  Int J Mol Sci       Date:  2016-08-25       Impact factor: 5.923

View more
  9 in total

Review 1.  The immunology of multiple sclerosis.

Authors:  Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger
Journal:  Nat Rev Immunol       Date:  2022-05-04       Impact factor: 53.106

2.  Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis.

Authors:  João Canto-Gomes; Carolina S Silva; Rita Rb-Silva; Daniela Boleixa; Ana Martins da Silva; Rémi Cheynier; Patrício Costa; Inés González-Suárez; Margarida Correia-Neves; João J Cerqueira; Claudia Nobrega
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

Review 3.  Regulatory Cells in Multiple Sclerosis: From Blood to Brain.

Authors:  Leticia Calahorra; Celia Camacho-Toledano; Mari Paz Serrano-Regal; María Cristina Ortega; Diego Clemente
Journal:  Biomedicines       Date:  2022-02-01

Review 4.  Transplant Tolerance, Not Only Clonal Deletion.

Authors:  Bruce M Hall; Nirupama D Verma; Giang T Tran; Suzanne J Hodgkinson
Journal:  Front Immunol       Date:  2022-04-21       Impact factor: 8.786

5.  Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination.

Authors:  Simon Faissner; Neele Heitmann; Carlos Plaza-Sirvent; Paulina Trendelenburg; Ulas Ceylan; Jeremias Motte; Clara Bessen; Doris Urlaub; Carsten Watzl; Oliver Overheu; Anke Reinacher-Schick; Kerstin Hellwig; Stephanie Pfaender; Ingo Schmitz; Ralf Gold
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

Review 6.  Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.

Authors:  Ruoyu Li; Hui Li; Xiaoyan Yang; Huiru Hu; Peidong Liu; Hongbo Liu
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

7.  Expression of T cell-related lncRNAs in multiple sclerosis.

Authors:  Maryam Dadyar; Bashdar Mahmud Hussen; Solat Eslami; Mohammad Taheri; Farhad Emadi; Soudeh Ghafouri-Fard; Arezou Sayad
Journal:  Front Genet       Date:  2022-08-26       Impact factor: 4.772

Review 8.  Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

Authors:  Rongzeng Liu; Shushu Du; Lili Zhao; Sahil Jain; Kritika Sahay; Albert Rizvanov; Vera Lezhnyova; Timur Khaibullin; Ekaterina Martynova; Svetlana Khaiboullina; Manoj Baranwal
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

9.  Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study.

Authors:  Ola Nakken; Trygve Holmøy; Hein Stigum; Kjell-Morten Myhr; Jesper Dahl; Einar Heldal; Haakon E Meyer
Journal:  Int J Epidemiol       Date:  2022-10-13       Impact factor: 9.685

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.